| Factor Information | |
|---|---|
| Data ID | 1588 |
| Factor | NT-pro-BNP (pg/mL) |
| Description | Riociguat also improved several secondary variables versus placebo, including PVR (−250±410 vs −66±632 dyn·s/cm5), NT-proBNP (−164±317 vs −46±697 pg/mL) and WHO FC (21%/79%/0% vs 8%/83%/8% improved/ stabilised/ worsened) |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | treatment |
| Objective | we explore the efficacy and safety of riociguat in the subgroup of patients with persistent/recurrent PAH after correction of congenital heart disease (PAH-CHD) from the PATENT studies. |
| Conclusion | Riociguat also improved several secondary variables versus placebo, including PVR (−250±410 vs −66±632 dyn·s/cm5), NT-proBNP (−164±317 vs −46±697 pg/mL) and WHO FC (21%/79%/0% vs 8%/83%/8% improved/ stabilised/ worsened) |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 543 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA/other |
| Reference | |
|---|---|
| PMID | 26135803 |
| Year | 2015 |
| Title | Riociguat for pulmonary arterial hypertension associated with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | adults with PAH-CHD | |
| Source | data | |
| Region | Cologne, Germany | |
| Method | retrospectively reviewed | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | corrective surgery | |
| Group | patients with Riociguat 2.5 mg– maximum(Treatment) | Placebo(Control) |
| Number | 13 | 12 |
| Age | 35±14 years | 40±16 years |
| Gender (Male: Female) | 2:13 | 2:10 |
| Marker Level | Change from baseline:-164±317 pg/mL | Change from baseline: -46±697 pg/mL |
